Bristol Myers Squibb Company (NYSE:BMY) Shares Sold by Impax Asset Management Group plc

Impax Asset Management Group plc lowered its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 11.3% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 131,431 shares of the biopharmaceutical company's stock after selling 16,815 shares during the quarter. Impax Asset Management Group plc's holdings in Bristol Myers Squibb were worth $8,016,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Pinney & Scofield Inc. acquired a new stake in Bristol Myers Squibb during the 4th quarter valued at approximately $25,000. Park Square Financial Group LLC purchased a new stake in Bristol Myers Squibb during the 4th quarter worth approximately $26,000. Fairway Wealth LLC acquired a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at about $28,000. Transce3nd LLC purchased a new position in Bristol Myers Squibb in the 4th quarter worth approximately $28,000. Finally, Global Wealth Strategies & Associates grew its position in shares of Bristol Myers Squibb by 137.5% in the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 275 shares in the last quarter. Institutional investors own 76.41% of the company's stock.

Insider Buying and Selling at Bristol Myers Squibb

In related news, EVP Samit Hirawat purchased 4,250 shares of the business's stock in a transaction dated Friday, April 25th. The stock was acquired at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the acquisition, the executive vice president directly owned 83,513 shares of the company's stock, valued at $3,973,548.54. This trade represents a 5.36% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.07% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb Stock Up 1.3%

Shares of Bristol Myers Squibb stock traded up $0.63 on Wednesday, reaching $47.67. 8,082,451 shares of the company were exchanged, compared to its average volume of 12,854,808. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17. Bristol Myers Squibb Company has a 1-year low of $39.71 and a 1-year high of $63.33. The company has a market cap of $97.01 billion, a P/E ratio of 17.85, a price-to-earnings-growth ratio of 1.38 and a beta of 0.36. The stock's 50 day moving average price is $47.65 and its 200-day moving average price is $53.46.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The company had revenue of $11.20 billion for the quarter, compared to analysts' expectations of $10.77 billion. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The firm's revenue for the quarter was down 5.6% on a year-over-year basis. During the same quarter last year, the company earned ($4.40) earnings per share. As a group, equities analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be issued a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.20%. The ex-dividend date of this dividend is Thursday, July 3rd. Bristol Myers Squibb's payout ratio is currently 92.88%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on BMY shares. UBS Group dropped their price objective on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating for the company in a report on Friday, April 11th. Argus upgraded Bristol Myers Squibb to a "hold" rating in a research report on Friday, April 25th. Jefferies Financial Group decreased their price target on Bristol Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research note on Wednesday, April 23rd. Wall Street Zen downgraded Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a research report on Friday, June 6th. Finally, Piper Sandler assumed coverage on shares of Bristol Myers Squibb in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $65.00 target price on the stock. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Bristol Myers Squibb presently has an average rating of "Hold" and an average price target of $58.00.

Bristol Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.